Cybin Inc. (CYBN) closed the last trading session at $8.46, gaining 7.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Cybin Inc. (CYBN) is a stock that can certainly grab the attention of many investors ...
(MENAFN- Investor Brand Network) Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company developing next-generation psychedelic-based treatments, has closed a private ...
We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Cybin Inc. (NYSEAMERICAN:CYBN) stands against the other psychedelic ...
The United States Patent and Trademark Office (USPTO) has granted U.S. patent 12,122,741, which claims the composition of matter of lead preclinical candidates in Cybin Inc’s (NYSE:CYBN) CYB005 ...
Cybin (NYSEMKT:CYBN) just reported results for the fourth quarter of 2023. Cybin reported earnings per share of -1 cent. This was above the analyst estimate for EPS of -4 cents. The company did not ...
Psychedelic substances like MDMA and psilocybin show great potential in treating patients with neurological or psychiatric problems. Therefore, drug development companies are showing an increasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results